Urinary Tract Infection Therapeutics Market Growth, Trends, Size, Revenue and Future Outlook
Urinary Tract Infection Therapeutics Market Size- By Drug, By Indication- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Jan-2024 | Report ID: HLCA2411 | Pages: 1 - 235 | Formats*: |
| Category : Healthcare | |||
Urinary Tract Infection Therapeutics Market Introduction and Overview
According to SPER Market Research, the Global Urinary Tract Infection Therapeutics Market is estimated to reach USD 12.13 Billion by 2033 with a CAGR of 3.1%.
The report includes an in-depth analysis of the Global Urinary Tract Infection Therapeutics Market, including market size and trends, product mix, applications, and supplier analysis. Infections that affect any component of the urinary system, such as the kidneys, bladder, ureters, and urethra, are referred to as urinary tract infections. Bacteria that enter the urinary tract through the urethra are the main cause of these illnesses. Symptoms of urinary tract infections (UTIs) include burning or pain when urinating, murky or bloody urine, and urgency. In order to avoid consequences and recurrent infections, prompt diagnosis and adequate treatment are essential.
- October 2021: The US Food and Drug Administration (FDA) received a new drug application (NDA) from Spero Therapeutics Inc. requesting clearance for tebipenem HBr tablets to treat complicated UTIs (cUTIs), including pyelonephritis, brought on by susceptible microorganisms.
- September 2021: Biapenem was introduced by BDR Pharma, a top generic pharmaceutical company in India, to treat patients with urinary tract infections, lower respiratory infections, and intra-abdominal infections.
Market Opportunities and Challenges
A greater emphasis on the creation of innovative medications is anticipated to offer substantial expansion opportunities for participants in the worldwide market for the treatment of urinary tract infections. It is anticipated that increased R&D will also offer profitable expansion opportunities for companies operating in the urinary tract infection treatment industry. Complicated UTIs are predicted to become more common during the projection period as a result of rising UTI recurrence rates, rising bacterial resistance in UTI patients, and overuse of antibiotics. The need for novel urinary tract infection treatments (drugs) is therefore anticipated to rise globally as a result, and this pattern is anticipated to persist throughout the projected period, propelling the market's expansion. Additionally, rising consumer awareness of the link between diabetes and obesity and bladder dysfunction, a greater emphasis on the creation of novel treatments, and the quick adoption of cutting-edge technologies for UTI treatment are some of the major trends propelling the market for urinary tract infection treatments as a whole.
The development of the worldwide urine tract infection treatment market is anticipated to be hampered by side effects related to the use of UTI medications. For example, the expansion of the urinary tract infection therapeutic market over the projected period may be hindered by side effects associated with UTI therapeutics like fluoroquinolones, such as fluctuations in blood sugar levels and central nervous system disorders like insomnia, seizures, and anxiety. The development of the worldwide market for treatments for urinary tract infections is also predicted to be hampered by a lack of awareness among people in developing and impoverished nations.
Market Competitive Landscape
The global market for treatments for urinary tract infections is very competitive, with a number of major companies present. To increase their market presence, these businesses concentrate on tactics including alliances, product launches, and mergers and acquisitions. The major key players in the Global Urinary Tract Infection Therapeutics Market are: Almirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Drug, By Indication |
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America |
| Companies Covered | Almirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others. |
COVID-19 Impact on Global Urinary Tract Infection Therapeutics Market
The market for treatments for urinary tract infections has been significantly impacted by the COVID-19 pandemic, as has the whole global healthcare sector. The market dynamics have been impacted by shifts in patient behaviour, disruptions in supply chains, and the reallocation of healthcare resources towards pandemic management. On the other hand, the long-term management of UTIs is probably going to benefit from the increased emphasis on infection prevention and cleanliness practices.
Key Target Audience:
- Pharmaceutical Companies
- Healthcare Providers
- Research and Development Teams
- Patients and Caregivers
- Health Insurance Providers
- Government Health Departments
- Pharmacy and Retail Chains
- Others
Our in-depth analysis of the Urinary Tract Infection Therapeutics Market includes the following segments:
| By Drug |
|
| By Indication |
|
| By Region: |
|
Key Topics Covered in the Report:
- Global Urinary Tract Infection Therapeutics Market Size (FY’2023-FY’2033)
- Overview of Global Urinary Tract Infection Therapeutics Market
- Segmentation of Global Urinary Tract Infection Therapeutics Market By Drug (Aminoglycoside Antibodies, Azoles and Amphotericin B, Cephalosporin, Nitrofurans, Penicillin and Combinations, Quinolones, Sulphonamides, Tetracycline, Other Drugs)
- Segmentation of Global Urinary Tract Infection Therapeutics Market By Indication (Complicated UTI, Neurogenic Bladder Infection, Recurring Complicated UTI, Uncomplicated UTI, Other Indications)
- Statistical Snap of Global Urinary Tract Infection Therapeutics Market
- Expansion Analysis of Global Urinary Tract Infection Therapeutics Market
- Problems and Obstacles in Global Urinary Tract Infection Therapeutics Market
- Competitive Landscape in the Global Urinary Tract Infection Therapeutics Market
- Impact of COVID-19 and Demonetization on Global Urinary Tract Infection Therapeutics Market
- Details on Current Investment in Global Urinary Tract Infection Therapeutics Market
- Competitive Analysis of Global Urinary Tract Infection Therapeutics Market
- Prominent Players in the Global Urinary Tract Infection Therapeutics Market
- SWOT Analysis of Global Urinary Tract Infection Therapeutics Market
- Global Urinary Tract Infection Therapeutics Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Urinary Tract Infection Therapeutics Market
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTER’s Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Urinary Tract Infection Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Urinary Tract Infection Therapeutics Market
7. Global Urinary Tract Infection Therapeutics Market, By Drug (USD Million)
7.1. Global Urinary Tract Infection Therapeutics Market Value Share and Forecast, By Drug, 2023-20337.2. Aminoglycoside Antibodies7.3. Azoles and Amphotericin B7.4. Cephalosporin7.5. Nitrofurans7.6. Penicillin and Combinations7.7. Quinolones7.8. Sulphonamides7.9. Tetracycline7.10. Other Drugs
8. Global Urinary Tract Infection Therapeutics Market, By Indication (USD Million)
8.1. Global Urinary Tract Infection Therapeutics Market Value Share and Forecast, By Indication, 2023-20338.2. Complicated UTI8.3. Neurogenic Bladder Infection8.4. Recurring Complicated UTI8.5. Uncomplicated UTI8.6. Other Indications
9. Global Urinary Tract Infection Therapeutics Market Forecast, 2019-2033 (USD Million)
9.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share
10. Global Urinary Tract Infection Therapeutics Market, By Drug, 2019-2033 (USD Million)
10.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Drug (2019-2026)10.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Drug (2027-2033)
11. Global Urinary Tract Infection Therapeutics Market, By Indication, 2019-2033 (USD Million)
11.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Indication (2019-2026)11.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Indication (2027-2033)
12. Global Urinary Tract Infection Therapeutics Market, By Region, 2019-2033 (USD Million)
12.1. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Region (2019-2026)12.2. Global Urinary Tract Infection Therapeutics Market Size and Market Share By Region (2027-2033)
12.3. Asia-Pacific12.3.1. Australia12.3.2. China12.3.3. India12.3.4. Japan12.3.5. South Korea12.3.6. Rest of Asia-Pacific12.4. Europe12.4.1. France12.4.2. Germany12.4.3. Italy12.4.4. Spain12.4.5. United Kingdom12.4.6. Rest of Europe12.5. Middle East and Africa12.5.1. Kingdom of Saudi Arabia12.5.2. United Arab Emirates12.5.3. Rest of Middle East & Africa12.6. North America12.6.1. Canada12.6.2. Mexico12.6.3. United States12.7. Latin America12.7.1. Argentina12.7.2. Brazil12.7.3. Rest of Latin America
13. Company Profile
13.1. Almirall SA13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments13.2. AstraZeneca13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments13.3. Bayer AG13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments13.4. Bristol-Myers Squibb Company13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments13.5. Cipla Inc.13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments13.6. Dr. Reddys Laboratories Ltd13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments13.7. GlaxoSmithKline PLC13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments13.8. Merck & Co. Inc13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments13.9. Novartis AG13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments13.10. Pfizer13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments13.11. Shionogi & Co. Ltd.13.11.1. Company details13.11.2. Financial outlook13.11.3. Product summary13.11.4. Recent developments13.12. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Urinary Tract Infection Therapeutics Market is projected to reach USD 12.13 billion by 2033, growing at a CAGR of 3.1% during the forecast period.
Urinary Tract Infection Therapeutics Market size from 2022. The Market is expected to reach USD 12.13 billion by 2033, at a CAGR of 3.1% during the forecast period.
Urinary Tract Infection Therapeutics Market CAGR of 3.1% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Urinary Tract Infection Therapeutics Market size is 12.13 billion from 2023 to 2033.
Urinary Tract Infection Therapeutics Market Segment is covered By Drug, By Indication.
The North America is anticipated to have the highest market share in the Urinary Tract Infection Therapeutics Market.
"The key players in the market include Companies Covered Almirall SA, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddys Laboratories Ltd, GlaxoSmithKline PLC, Merck & Co. Inc, Novartis AG, Pfizer, Shionogi & Co. Ltd., Others."
Complicated UTIs are predicted to become more common during the projection period as a result of rising UTI recurrence rates, rising bacterial resistance in UTI patients, and overuse of antibiotics.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
